The pres­sure builds for Em­ma Walm­s­ley as Glax­o­SmithK­line miss­es Q1 pro­jec­tion, drops more can­cer drugs

Glax­o­SmithK­line CEO Em­ma Walm­s­ley is stay­ing fo­cused on the com­pa­ny’s split as earn­ings slide and El­liott Man­age­ment lurks on the side­lines, threat­en­ing to launch one of its no­to­ri­ous ac­tivist at­tacks aimed to shake things up. And in a Q1 marked by a cou­ple of ma­jor set­backs on the on­col­o­gy side, R&D chief Hal Bar­ron is do­ing some fine tun­ing of the pipeline that in­cludes drop­ping two ear­ly stage can­di­dates for can­cer and Duchenne mus­cu­lar dy­s­tro­phy (DMD).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER